Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V STEFANSSON

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Science Illustrated|March 19, 2010
Our neglected ArcticV STEFANSSON
Diabetologia|June 17, 2016
Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairmentPaola Fioretto, Bergur V Stefansson, Eva Johnsson, et al.
Scandinavian Journal of Immunology|March 25, 2005
Increased frequency of C4B*Q0 alleles in patients with Henoch-Schönlein purpuraV Stefansson Thors, R Kolka, S L Sigurdardottir, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 26, 2018
Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney diseaseClaire C J Dekkers, David C Wheeler, C David Sjöström, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 16, 2018
Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney diseaseClaire C J Dekkers, David C Wheeler, C David Sjöström, et al.
BMC Nephrology|June 23, 2018
Contemporary rates and predictors of fast progression of chronic kidney disease in adults with and without diabetes mellitusAlan S Go, Jingrong Yang, Thida C Tan, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 22, 2019
Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markersNienke M A Idzerda, Bergur V Stefansson, Michelle J Pena, et al.
Diabetes, Obesity & Metabolism|November 11, 2018
Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markersHiddo J L Heerspink, C David Sjöström, Silvio E Inzucchi, et al.
BMJ Open|February 2, 2022
Loop and thiazide diuretic use and risk of chronic kidney disease progression: a multicentre observational cohort studyJesse K Fitzpatrick, Jingrong Yang, Andrew P Ambrosy, et al.
Clinical Journal of the American Society of Nephrology : CJASN|June 25, 2016
Effect of Tenapanor on Interdialytic Weight Gain in Patients on HemodialysisGeoffrey A Block, David P Rosenbaum, Maria Leonsson-Zachrisson, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Science Illustrated|March 19, 2010
Our neglected ArcticV STEFANSSON
Diabetologia|June 17, 2016
Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairmentPaola Fioretto, Bergur V Stefansson, Eva Johnsson, et al.
Scandinavian Journal of Immunology|March 25, 2005
Increased frequency of C4B*Q0 alleles in patients with Henoch-Schönlein purpuraV Stefansson Thors, R Kolka, S L Sigurdardottir, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 26, 2018
Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney diseaseClaire C J Dekkers, David C Wheeler, C David Sjöström, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 16, 2018
Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney diseaseClaire C J Dekkers, David C Wheeler, C David Sjöström, et al.
BMC Nephrology|June 23, 2018
Contemporary rates and predictors of fast progression of chronic kidney disease in adults with and without diabetes mellitusAlan S Go, Jingrong Yang, Thida C Tan, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 22, 2019
Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markersNienke M A Idzerda, Bergur V Stefansson, Michelle J Pena, et al.
Diabetes, Obesity & Metabolism|November 11, 2018
Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markersHiddo J L Heerspink, C David Sjöström, Silvio E Inzucchi, et al.
BMJ Open|February 2, 2022
Loop and thiazide diuretic use and risk of chronic kidney disease progression: a multicentre observational cohort studyJesse K Fitzpatrick, Jingrong Yang, Andrew P Ambrosy, et al.
Clinical Journal of the American Society of Nephrology : CJASN|June 25, 2016
Effect of Tenapanor on Interdialytic Weight Gain in Patients on HemodialysisGeoffrey A Block, David P Rosenbaum, Maria Leonsson-Zachrisson, et al.
Pageof 3